ArticleBMC medical imaging2026
A nomogram combined substantia nigra hyperechogenicity with third ventricular width assessed by transcranial sonography in prediction Parkinson's disease-related cognitive impairment.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo develop a nomogram that incorporating clinical data and transcranial sonography (TCS) markers for predicting Parkinson's disease patients with cognitive impairment (PD-CI).
methods149 PD with normal cognition (PD-NCI), 117 PD with mild CI (PD-MCI), and 79 PD with dementia (PDD) were included as the training set, 145 PD patients and 154 age- and gender-matched volunteers were enrolled as the test set and control group, respectively. Logistic regression was utilized to screen risk factors for predicting PD-CI, and a nomogram was generated.
resultsA predictive model was developed using age, education level, homocysteine, substantia nigra hyperechogenicity (SNH), and third ventricle (V3) width. Receiver operating characteristic curves indicated that V3 width, homocysteine, and the model effectively distinguished between PD-NCI and PD-CI, PDD and non-PDD, as well as PDD and PD-MCI, with the predictive model yielding the highest area under the curve. Calibration curves showed that the predictions of the final model in both the training and test sets closely matched the actual probabilities, while clinical decision curves suggested that the nomogram provided a substantial clinical net benefit.
conclusionA predictive model for PD-CI that incorporates age, education level, plasma homocysteine levels, SNH, and V3 width has been developed and validated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.